Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of nivolumab alone or with ipilimumab in children and young adults with high-grade metastatic central nervous system tumors
MOH_2017-12-11_000486Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in Neuro-Oncological Malignancies and brain neoplasm (2 arms), sponsored by Bristol Myers Squibb. Started Nov 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Neuro-Oncological Malignanciesbrain neoplasm
Beyond the preview
Go deeper on MOH_2017-12-11_000486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-11_000486.